Timolol LA: A double-masked, active-controlled, randomized, crossover, comfort, ocular safety, and systemic bioavailability study in healthy volunteers

Current Medical Research and Opinion

Volumn 21, Issue 3, 2005, Pages 369-373

  Mundorf, Thomas K ^a   Ogawa, Takahiro ^b   Inui, Noritsugu ^b   Naka, Hiroaki ^b   Novack, Gary D ^a,c   Crockett, R Stephens ^a  

^a Senju Pharmaceutical Co Ltd ^*  (United States)

^b SENJU PHARMACEUTICAL CO LTD   (Japan)

^c Pharma Logic Development Inc   (United States)

Author keywords

Formulation; Pharmacokinetics; Safety; Timolol

Indexed keywords

SORBIC ACID; TIMOLOL; TIMOLOL MALEATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; EVALUATION; EYE BURNING; FEMALE; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR PRESSURE; LACRIMATION; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

EID: 16844379757     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X36378     Document Type: Article

References (13)

1. Boger WP, Steinert RF, Puliafito CA, Pavan-Langston D. Clinical trial comparing timolol ophthalmic solution to pilocarpine in open-angle glaucoma. Am J Ophthalmol 1978;86:8-18
2. Yalon M, Urinowsky E, Rothkoff L. Frequency of timolol administration. Am J Ophthalmol 1981;92:526-9
3. Soil DB. Evaluation of timolol in chronic open-angle glaucoma: once-a-day vs twice-a-day. Arch Ophthalmol 1980;98:2178-81
4. Wandel T, Charap AD, Lewis RA, et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986;101:298-304
5. DuBiner HB, Hill R, Kaufman H, et al. Timolol hemihydrate vs timolol maleate to treat ocular hypertension and open-angle glaucoma. Am J Ophthalmol 1996;121:522-8
6. Laurence J, Holder D, Vogel R, et al. A double-masked, placebo-controlled evaluation of timolol in gel vehicle. J Glaucoma 1993;2:177-82
7. Shedden AH. Timolol maleate in gel-forming solution: a novel formulation of timolol maleate. Chibret Int J Ophthalmol 1994;10:32-6
8. Higashiyama M, Inada K, Ohtori A, Tojo K. Improvement of the ocular bioavailability of timolol by sorbic acid. Int J Pharmaceut 2004;272:91-8
9. Mundorf TK, Ogawa T, Naka H, et al. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of Timolol-LA once daily and timolol maleate solution twice daily in the treatment of adults with ocular hypertension or open-angle glaucoma. Clin Ther 2004;26:541-51
10. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984;102:551-3
11. Passo MS, Palmer EA, van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984;91:1361-3
12. Alvan G, Calissendorff B, Seideman P, et al. Absorption of ocular timolol. Clinical Pharmacokinetics 1980;5:95-100
13. Bobik A, Jennings GL, Ashley P, Korner PI. Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administration. Eur J Clin Pharmacol 1979; 16:243-9